Stock listing

LSE:THAT Thalia Therapeutics PLC Share Price

Home listing (LSE) of Thalia Therapeutics PLC

Follow Thalia Therapeutics PLC into a list and get an email when it puts out news.

Share price · LSE:THAT

0.575p GBX (pence) 0.000 (0.0%)

Close on Nov 20, 2026

Past year -8.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
0.562p – 0.575p GBX (pence)Nov 20, 2026
Volume
427,173 sharesNov 20, 2026
Market cap
£10.21M GBPAt the close on Nov 20, 2026 · price × 1.78B shares outstanding
52-week range
0.400p – 0.950p GBX (pence)Lowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
£4,983 GBPMedian day 405,366 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Thalia Therapeutics PLC logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
LSE:THAT · Home0.575p GBX (pence)0.000 (0.0%)427,1730.575p0.575p0.562p0.575pClose on Nov 20, 2026
Frankfurt:0GO€0.0050 EUR0.0000 (0.0%)—€0.0050€0.0050€0.0050€0.0050Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · LSE:THAT · GBX (pence), adjusted for splits

DayCloseChange%OpenHighLowVolume
0.575p0.0000.0%0.575p0.575p0.562p427,173
0.575p0.0000.0%0.575p0.575p0.550p66,481
0.575p0.0000.0%0.575p0.575p0.565p1,011,418
0.575p0.0000.0%0.570p0.600p0.550p228,872
0.575p0.0000.0%0.535p0.600p0.500p2,587,591
0.575p0.0000.0%0.551p0.600p0.550p3,237,358
0.575p+0.025+4.5%0.585p0.600p0.550p1,619,882
0.550p0.0000.0%0.550p0.550p0.518p2,011,818
0.550p-0.025-4.3%0.552p0.600p0.500p3,702,796
0.575p0.0000.0%0.575p0.575p0.550p54,102
0.575p0.0000.0%0.575p0.575p0.551p371,130
0.575p0.0000.0%0.575p0.575p0.551p27,087
0.575p0.0000.0%0.575p0.575p0.550p14,294
0.575p0.0000.0%0.575p0.575p0.550p14,294
0.575p0.0000.0%0.575p0.575p0.550p20,000
0.575p0.0000.0%0.575p0.575p0.550p752,173
0.575p0.0000.0%0.575p0.575p0.550p300,000
0.575p0.0000.0%0.600p0.600p0.573p1,259,868
0.575p0.0000.0%0.600p0.600p0.573p536,216
0.575p-0.025-4.2%0.600p0.600p0.571p142,491
0.600p0.0000.0%0.600p0.630p0.576p18,295
0.600p-0.025-4.0%0.603p0.603p0.600p430,337
0.625p+0.001+0.2%0.625p0.635p0.603p170,000
0.624p-0.001-0.2%0.624p0.624p0.600p635,370
0.625p0.0000.0%0.625p0.650p0.600p66,954
0.625p0.0000.0%0.625p0.639p0.600p31,491
0.625p0.0000.0%0.650p0.650p0.603p1,000,347
0.625p0.0000.0%0.625p0.625p0.600p64,592
0.625p0.0000.0%0.625p0.625p0.600p42,536
0.625p0.0000.0%0.625p0.650p0.600p9,115
0.625p0.0000.0%0.625p0.650p0.600p398,164
0.625p0.0000.0%0.625p0.650p0.600p648,882
0.625p0.0000.0%0.625p0.625p0.600p121,919
0.625p0.0000.0%0.625p0.650p0.600p502,753
0.625p0.0000.0%0.625p0.650p0.625p156,922
0.625p0.0000.0%0.625p0.650p0.600p1,416,838
0.625p0.0000.0%0.625p0.650p0.613p1,062,619
0.625p+0.025+4.2%0.600p0.650p0.600p1,885,245
0.600p0.0000.0%0.600p0.650p0.550p1,251
0.600p+0.025+4.3%0.600p0.650p0.550p1,928,060
0.575p0.0000.0%0.575p0.599p0.550p1,015,064
0.575p0.0000.0%0.575p0.600p0.550p253,537
0.575p0.0000.0%0.575p0.600p0.550p565,424
0.575p0.0000.0%0.575p0.600p0.550p770,787
0.575p0.0000.0%0.575p0.600p0.550p187,256
0.575p0.0000.0%0.575p0.600p0.550p419,410
0.575p0.0000.0%0.575p0.600p0.550p756,020
0.575p+0.025+4.5%0.600p0.650p0.550p7,773,544
0.550p0.0000.0%0.550p0.600p0.500p23,797
0.550p0.0000.0%0.550p0.600p0.516p2,584,147
0.550p0.0000.0%0.550p0.600p0.550p2,306
0.550p0.0000.0%0.550p0.600p0.500p38,722
0.550p-0.025-4.3%0.575p0.600p0.500p2,574,838
0.575p-0.050-8.0%0.625p0.650p0.550p4,360,358
0.625p0.0000.0%0.625p0.650p0.601p66,505
0.625p0.0000.0%0.625p0.650p0.600p405,366
0.625p-0.025-3.8%0.650p0.650p0.600p434,717
0.650p0.0000.0%0.650p0.675p0.605p2,031,397
0.650p0.0000.0%0.650p0.700p0.621p788,379
0.650p0.0000.0%0.650p0.700p0.600p765,353
0.650p0.0000.0%0.650p0.700p0.600p29,312
0.650p0.0000.0%0.650p0.700p0.600p140,490
0.650p0.0000.0%0.650p0.700p0.620p168,214
0.650p0.0000.0%0.650p0.650p0.650p107,932
0.650p0.0000.0%0.650p0.700p0.600p124,736

Splits

2 splits since 2015 · LSE:THAT · every price before a split is adjusted for it

DayRatioWhat
1-for-4Consolidation
1-for-10Consolidation
Ticker
LSE:THAT
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
LSE
Currency
GBX

What changed lately

Latest news

Interim Results

Sep 30, 2026

Closed 0.625p (0.0%) on Sep 30, 2026

New Patent Granted for miRisten in China

Sep 29, 2026

Closed 0.625p (+4.2%) on Sep 29, 2026

Business Update and Notice of Results

Sep 15, 2026

Closed 0.575p (+4.5%) on Sep 15, 2026

Grant of Director Share Options

Jul 23, 2026

Closed 0.70p (0.0%) on Jul 23, 2026

Acquisition and £2.75 million Fundraise

Jun 24, 2026

Closed 0.675p (+17.4%) on Jun 24, 2026

All Thalia Therapeutics PLC news

Thalia Therapeutics PLC on 6ix

Sector
Health care
Industry
Biotechnology
News releases
18 in the last 12 months · 134 in all · newest Nov 16, 2026 · oldest 2017
Calls
4 calls with a replay · 4 with a transcript · latest Sep 30, 2026
Decks
1 deck · latest Oct 2, 2023

Where Thalia Therapeutics PLC is listed

ListingExchangeCountryCurrency
LSE:THAT · Home listing · This pageLSEUnited KingdomGBX
LS Exchange:A2DQESLS ExchangeGermanyEUR
Lang & Schwarz:A2DQESLang & SchwarzGermanyEUR
Stuttgart:0GOStuttgartGermanyEUR
AQUIS:THAT.GBAQUISUnited KingdomGBX
Frankfurt:0GOFrankfurtGermanyEUR

Valuation

EV/sales 1,199× against a median of 2.2×: the highest of 5 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
£8.71M GBP
P/E
Loss
EV/sales
1,199×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
4.2×
Gross margin
100.0%
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Thalia Therapeutics PLC · LSE:THATUS$13.36MUS$11.39Mn/a1,199×n/a4.2×n/a0.0×n/a
Actuate Therapeutics, Inc. · NASDAQ:ACTUUS$13.60MUS$11.50Mn/an/an/an/an/an/a1.75
BeyondSpring, Inc. · NASDAQ:BYSIUS$13.57MUS$12.99M0.3×n/an/a0.9×n/a0.0×1.31
Acumen Pharmaceuticals, Inc. · NASDAQ:ABOSUS$13.49M−US$38.84Mn/an/an/a0.4×n/a0.8×1.45
Pharma Equity Group A/S Class A · OMXCOP:PEGUS$13.47MUS$15.05Mn/an/a52.8×3.6×n/a0.4×n/a
BioInvent International AB · OMXSTO:BINVUS$13.45M−US$6.62Mn/a−1.7×n/a0.7×n/a0.1×n/a
Celyad Oncology SA · EURONEXT:CYADUS$13.31MUS$13.21M14.6×573×n/a9.7×n/a0.0×n/a
Defence Therapeutics Inc Class A · CSE:DTCUS$13.27MUS$13.16Mn/an/an/a5.4×n/a0.5×0.74
Tvardi Therapeutics, Inc. · NASDAQ:TVRDUS$13.22M−US$9.05Mn/an/an/a0.9×n/a0.0×1.89
Diamyd Medical AB Class B · OMXSTO:DMYD_BUS$13.22M−US$16.66Mn/a−357×n/a0.6×n/a0.0×n/a
Devonian Health Group, Inc. · TSXV:GSDUS$13.09MUS$12.59Mn/a6.0×n/a2.7×−204.1%0.0×0.12
Median of the othersUS$13.38MUS$12.05M7.5×2.2×52.8×0.9×−204.1%0.0×1.38

Team and board

Officers

OfficerRole
David H SolomonChief Executive Officer
Luke CairnsChief Financial Officer
Sarah HollinsInvestor Relations

Board

DirectorRole
Chris BrittenNon-Executive Chairman
Alastair SmithNon-Executive Director
Edward WardleNon-Executive Director
Michael G. PalfreymanNon-Executive Director

Events

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (October 2023)Investor deck18 slidesOct 2, 2023

Open Decks

Financings

RaiseDateIn US dollars
Private placement of new ordinary shares
Update: £2.75M
Buyers: NLC Health Impact Fund Cooperatof U.A. (29,166,667 Second Fundraise Shares)
Jul 17, 2026US$3.7M
Private placement of second Issue Shares (ordinary shares) with Fundraise Warrants
Closed: private placement
Apr 22, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in GBP

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue7.26K7.28K1.95K001.16M
Cost of revenue934.0K
Gross profit7.26K7.28K1.95K221.0K
Research and development91.9K390.4K619.4K577.5K1.18M900.4K216.9K846.2K409.8K
Selling, general and administrative795.4K551.6K718.0K615.7K663.9K664.0K730.4K643.7K316.6K249.0K
Operating income-1.10M-1.22M-1.43M-1.19M-1.84M-1.56M-947.0K-1.49M-726.0K-28.0K
Depreciation and amortization89.2K228.5K236.6K171.9K161.1K281.3K6.00K
EBITDA-1.34M-964.5K-1.61M-775.1K-1.33M-444.7K-22.0K
Interest expense1.96K1.39K9815.30K5.86K
Income before tax-1.10M-1.22M-1.43M-1.19M-1.84M-1.57M-949.0K-1.39M-1.93M-22.0K
Income tax104.1K-101.0K-148.0K-164.0K-298.0K-262.0K-72.4K-206.0K-89.9K-14.4K
Net income-1.21M-1.06M-1.27M-1.03M-1.54M-1.30M-876.0K-1.19M-1.84M-22.0K
Earnings per share, basic-0.00-0.00-0.01-0.01-0.01-0.01-0.01-0.01-0.03-0.00

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents1.08M626.0K1.03M1.92M1.78M3.56M965.8K793.1K1.33M172.0K
Receivables73.7K134.7K176.4K209.6K551.3K254.8K87.5K265.1K163.0K23.2K
Inventory-265.1K-132.7K232.0K
Current assets1.17M775.8K1.21M2.17M2.34M3.83M1.07M1.07M1.46M601.0K
Goodwill061.2K0
Total assets1.17M775.8K1.28M2.17M2.34M3.83M1.07M1.07M1.46M1.12M
Accounts payable27.0K23.3K20.2K35.8K180.3K116.9K27.2K113.1K79.5K
Current liabilities98.0K124.4K81.7K77.9K212.7K169.1K77.7K190.1K179.2K77.0K
Total debt204.9K
Total liabilities98.0K124.4K81.7K77.9K212.7K169.1K77.7K190.1K179.2K77.0K
Shareholders' equity1.07M647.6K1.13M2.09M2.13M3.66M987.3K879.9K1.28M1.04M
Shares outstanding724.4M340.9M242.9M186.4M181.1M136.3M100.2M91.3M64.8M34.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-1.16M-971.5K-1.21M-828.3K-1.77M-1.38M-806.0K-1.34M-950.8K-376.0K
Capital spending-500-3000000
Free cash flow-1.16M-971.5K-1.21M-828.3K-1.77M-1.38M-806.0K-1.34M-950.8K-376.0K
Cash from investing78127.7K403.0K-39.0K
Cash from financing1.61M570.4K315.9K963.8K6773.97M978.6K783.4K1.85M119.9K
Change in cash453.3K-401.1K-892.4K135.5K-1.77M2.59M172.6K-533.1K1.31M-415.0K

Open Financials

Cap table

Built by 6ix from Thalia Therapeutics PLC’s releases · as of Apr 22, 2025

Common shares
1,775,720,897
Fully diluted
1,775,720,897

Fully diluted

LineShares
Common shares1,775,720,897

Share count over time

CountShares
Nov 22, 20261,775,720,897

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Alastair SmithNon-Executive Director · Since at least Sep 30, 2026
Chris BrittenNon-Executive Chairman · Since at least Sep 30, 2026
David H SolomonChief Executive Officer · Since at least Sep 30, 2026
Edward WardleNon-Executive Director · Since at least Jul 17, 2026
Luke CairnsChief Financial Officer · Since at least Sep 30, 2026
Michael G. PalfreymanNon-Executive Director · Since at least Sep 30, 2026
Sarah HollinsInvestor Relations · Since at least Apr 20, 2026

Open People

Log in to ask 6ix AI your own questions about Thalia Therapeutics PLC.